A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Trial Details

NCT ID
NCT06533059
Phase
PHASE1
Sponsor
Alterome Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • ALTA2618
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Histologically confirmed diagnosis of a solid tumor malignancy harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based…
  • Unresectable or metastatic disease
  • Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and …
  • Evaluable or measurable disease per RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →